# BCMA Bispecific Antibody Therapy for Post-BCMA CAR T-Cell Therapy Relapse (RECLAIM)

> **NCT07009899** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Medical College of Wisconsin** · enrollment: 34 (estimated)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** Linvoseltamab

## Key facts

- **NCT ID:** NCT07009899
- **Lead sponsor:** Medical College of Wisconsin
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-07-01
- **Primary completion:** 2028-02-01
- **Final completion:** 2029-02-01
- **Target enrollment:** 34 (ESTIMATED)
- **Last updated:** 2026-05-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07009899

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07009899, "BCMA Bispecific Antibody Therapy for Post-BCMA CAR T-Cell Therapy Relapse (RECLAIM)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT07009899. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*